cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Abcellera Biologics Inc
43 own
35 watching
Current Price
$6.97
$0.02
(0.29%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,010.33M
52-Week High
52-Week High
14.97
52-Week Low
52-Week Low
5.53
Average Volume
Average Volume
2.71M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,010.33M
icon52-Week High14.97
icon52-Week Low5.53
iconAverage Volume2.71M
iconDividend Yield--
iconP/E Ratio--
What does the Abcellera Biologics Inc do?
Our mission is to improve health with technologies that transform the way that antibody-based therapies are discovered. We aim to become the centralized operating system for next generation antibody discovery. Our full-stack, artificial intelligence-, or AI, powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. --- We were incorporated in 2012 under the Business Corporations Act (British Columbia), or the BCBCA. Our principal executive offices are located at 2215 Yukon Street Vancouver, British Columbia, V5Y 0A1, Canada and our telephone number is (604) 559-9005. We have six wholly owned subsidiaries, Lineage, a Delaware corporation, Trianni, a California corporation, AbCellera US Holdings Inc., a Delaware corporation, AbCellera Properties Inc., a BCBCA company, AbCellera Properties Columbia Inc., a BCBCA company, and Channel Biologics Pty Ltd., a proprietary company registered in New South Wales, Australia. Our website address is www.abcellera.com.
Read More
How much money does Abcellera Biologics Inc make?
News & Events about Abcellera Biologics Inc.
Business Wire
1month ago
AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19, 2023...
Business Wire
2 months ago
AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV). The partnership aims to provide...
Ticker Report
3 months ago
Cowen assumed coverage on shares of AbCellera Biologics (NASDAQ:ABCL Get Rating) in a research report released on Tuesday, Marketbeat reports. The firm issued an outperform rating on the stock. Other research analysts have also issued research reports about the company. The Goldman Sachs ...
Ticker Report
4 months ago
AbCellera Biologics Inc. (NASDAQ:ABCL Get Rating) was the recipient of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 15,350,000 shares, a decline of 7.0% from the November 30th total of 16,510,000 shares. ...
Business Wire
6 months ago
AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) announced today that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCelleras antibody...
Frequently Asked Questions
Frequently Asked Questions
What is Abcellera Biologics Inc share price today?
plus_minus_icon
Can Indians buy Abcellera Biologics Inc shares?
plus_minus_icon
How can I buy Abcellera Biologics Inc shares from India?
plus_minus_icon
Can Fractional shares of Abcellera Biologics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Abcellera Biologics Inc stocks?
plus_minus_icon
What is today’s traded volume of Abcellera Biologics Inc?
plus_minus_icon
What is today’s market capitalisation of Abcellera Biologics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Abcellera Biologics Inc?
plus_minus_icon
What percentage is Abcellera Biologics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Abcellera Biologics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$6.97
$0.02
(0.29%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PULMONX CORP
PULMONX CORP
$12.01
$0.50 (4.34 %)
Valneva SE
Valneva SE
$11.40
$-0.31 (-2.65 %)
Zomedica Corp
Zomedica Corp
$0.20
$0.00 (1.33 %)
Fusion Pharmaceuticals Inc
Fusion Pharmaceuticals Inc
$5.10
$0.78 (18.06 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
PULMONX CORP
PULMONX CORP
$12.01
$0.50 (4.34 %)
Valneva SE
Valneva SE
$11.40
$-0.31 (-2.65 %)
Zomedica Corp
Zomedica Corp
$0.20
$0.00 (1.33 %)
Fusion Pharmaceuticals Inc
Fusion Pharmaceuticals Inc
$5.10
$0.78 (18.06 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00